CHRS FY 2022 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$211M-35.4% YoY

Gross Profit

$141M66.8% margin

Operating Income

-$257M-121.7% margin

Net Income

-$292M-138.2% margin

EPS (Diluted)

$-3.76

Cash Flow

Operating Cash Flow

-$241M

Free Cash Flow

-$243M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$481M

Total Liabilities

$618M

Stockholders' Equity

-$137M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$327M	-35.4%
Gross Profit	$141M	$269M	-47.6%
Operating Income	-$257M	-$264M	+2.6%
Net Income	-$292M	-$287M	-1.6%